Übersicht – Systemische Therapie des hepatozellulären Karzinoms

Das hepatozelluläre Karzinom (HCC) ist weltweit der siebthäufigste Tumor (fünfthäufigste bei Männern, achthäufigste bei Frauen). Aufgrund der anhaltend unzureichenden Behandlungsoptionen für Patienten im fortgeschrittenen Tumorstadium ist das HCC die dritthäufigste tumorvermittelte Todesursache (www.iarc.fr). 2008 waren entsprechend der schlechten Prognose dieser Tumorerkrankung bei 748 300 Neuerkrankungen 695 900 Todesfälle zu verzeichnen.

• Literatur

• 1 Berhane S, Toyoda H, Tada T et al. Role of the Galad and Balad-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. Clin Gastroenterol Hepatol 2016; DOI: 10.1016/j.cgh.2015.12.042.
• 2 Johnson PJ, Berhane S, Kagebayashi C et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015; 33: 550-558
• 3 Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
• 4 Ren Z, Zhu K, Kang H et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015; 33: 894-900
• 5 Bruix J, Takayama T, Mazzaferro V et al. STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). J Clin Oncol 2014; 32: 5s
• 6 Lencioni R, Llovet JM, Han G et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol 2016; DOI: 10.1016/j.jhep.2016.01.012.
• 7 Johnson PJ, Qin S, Park JW et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31: 3517-3524
• 8 Kudo M, Han G, Finn RS et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatol 2014; 60: 1697-1707
• 9 Zhu AX, Park JO, Ryoo BY et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015; 16: 859-870
• 10 Bruix J, Tak WY, Gasbarrini A et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer 2013; 49: 3412-3419
• 11 Ikeda M, Okusaka T, Mitsunaga S et al. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2016; 22: 1385-1394
• 12 Geissler EK, Schnitzbauer AA, Zulke C et al. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplant 2016; 100: 116-125
• 13 Zhu AX, Kudo M, Assenat E et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014; 312: 57-67
• 14 Verslype C, Cohn A, Kelley R et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2012; 30 (suppl) 240s abstr 4007
• 15 Santoro A, Rimassa L, Borbath I et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013; 14: 55-63